• Denali Therapeutics agreed to sell a Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 195 million.
• The voucher was awarded following FDA accelerated approval of AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome in March 2026.
• Proceeds are slated to fund development of Denali’s TransportVehicle-enabled pipeline in lysosomal storage disorders and neurodegenerative diseases.
• Closing remains subject to customary conditions, including expiration of the Hart-Scott Rodino waiting period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Denali Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001714899-26-000081), on June 18, 2026, and is solely responsible for the information contained therein.